

# Edward T Morgan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9227449/publications.pdf>

Version: 2024-02-01

80  
papers

4,874  
citations

109321  
35  
h-index

91884  
69  
g-index

85  
all docs

85  
docs citations

85  
times ranked

3909  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of Cytochromes P450 During Inflammation and Infection. Drug Metabolism Reviews, 1997, 29, 1129-1188.	3.6	440
2	REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATION. Annual Review of Pharmacology and Toxicology, 2006, 46, 123-149.	9.4	398
3	Impact of Infectious and Inflammatory Disease on Cytochrome P450-Mediated Drug Metabolism and Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2009, 85, 434-438.	4.7	391
4	Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes. Drug Metabolism and Disposition, 2007, 35, 1687-1693.	3.3	319
5	Comparison of six rabbit liver cytochrome P-450 isozymes in formation of a reactive metabolite of acetaminophen. Biochemical and Biophysical Research Communications, 1983, 112, 8-13.	2.1	148
6	Bimodal Regulation of Ceramidase by Interleukin-1 <sup>2</sup> . Journal of Biological Chemistry, 1997, 272, 18718-18724.	3.4	146
7	Metabolomics Reveals that Hepatic Stearoyl-CoA Desaturase 1 Downregulation Exacerbates Inflammation and Acute Colitis. Cell Metabolism, 2008, 7, 135-147.	16.2	144
8	Cancer, Inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents. Clinical Pharmacology and Therapeutics, 2014, 96, 449-457.	4.7	120
9	Hepatic Cytochrome P450 Regulation in Disease States. Current Drug Metabolism, 2001, 2, 165-183.	1.2	102
10	Hypothalamo-Pituitary Regulation of Cytochrome P-450 15 <sup>2</sup> Apoprotein Levels in Rat Liver*. Endocrinology, 1985, 117, 2085-2092.	2.8	99
11	Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology, 2002, 181-182, 207-210.	4.2	94
12	Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1994, 1219, 475-483.	2.4	89
13	Suppression of CYP2C11 Gene Transcription by Interleukin-1 Mediated by NF- $\kappa$ B Binding at the Transcription Start Site. Archives of Biochemistry and Biophysics, 2000, 377, 187-194.	3.0	88
14	TRANSCRIPTIONAL SUPPRESSION OF CYTOCHROME P450 GENES BY ENDOGENOUS AND EXOGENOUS CHEMICALS. Drug Metabolism and Disposition, 2004, 32, 367-375.	3.3	86
15	Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1 <sup>2</sup> and endotoxin in primary rat hepatocytes. Biochemical Pharmacology, 1997, 54, 729-737.	4.4	85
16	Effects of early maternal separation on ethanol intake, GABA receptors and metabolizing enzymes in adult rats. Psychopharmacology, 2005, 181, 8-15.	3.1	77
17	Regulation of Cytochrome P450 2C11 (CYP2C11) Gene Expression by Interleukin-1, Sphingomyelin Hydrolysis, and Ceramides in Rat Hepatocytes. Journal of Biological Chemistry, 1995, 270, 25233-25238.	3.4	76
18	Hepatic Cytochrome P450 Gene Regulation during Endotoxin-Induced Inflammation in Nuclear Receptor Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 703-709.	2.5	75

#	ARTICLE	IF	CITATIONS
19	Down-Regulation of Cytochrome P450 mRNAs and Proteins in Mice Lacking a Functional NOS2 Gene. <i>Molecular Pharmacology</i> , 1998, 54, 273-279.	2.3	72
20	Down-regulation of multiple cytochrome p450 gene products by inflammatory mediators in vivo. <i>Biochemical Pharmacology</i> , 1993, 45, 415-419.	4.4	69
21	Nitric Oxide-dependent Proteasomal Degradation of Cytochrome P450 2B Proteins. <i>Journal of Biological Chemistry</i> , 2008, 283, 889-898.	3.4	65
22	EXPRESSION OF UDP-GLUCURONOSYLTRANSFERASE ISOFORM mRNAs DURING INFLAMMATION AND INFECTION IN MOUSE LIVER AND KIDNEY. <i>Drug Metabolism and Disposition</i> , 2006, 34, 351-353.	3.3	63
23	MODULATION OF DRUG METABOLISM IN INFECTIOUS AND INFLAMMATORY DISEASES*. <i>Drug Metabolism Reviews</i> , 1999, 31, 29-41.	3.6	62
24	Dual Mechanisms of CYP3A Protein Regulation by Proinflammatory Cytokine Stimulation in Primary Hepatocyte Cultures. <i>Drug Metabolism and Disposition</i> , 2009, 37, 865-872.	3.3	59
25	Rapid Transcriptional Suppression of Rat Cytochrome P450 Genes by Endotoxin Treatment and Its Inhibition by Curcumin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 1205-1212.	2.5	57
26	Changes in the rat hepatic mixed function oxidase system associated with chronic ethanol vapor inhalation. <i>Biochemical Pharmacology</i> , 1981, 30, 595-600.	4.4	55
27	Role of Nitric Oxide in Down-Regulation of CYP2B1 Protein, but Not RNA, in Primary Cultures of Rat Hepatocytes. <i>Molecular Pharmacology</i> , 2001, 60, 209-216.	2.3	47
28	Transcriptional and post-transcriptional suppression of P450IIC11 and P450IIC12 by inflammation. <i>FEBS Letters</i> , 1990, 271, 59-61.	2.8	46
29	Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. <i>Free Radical Biology and Medicine</i> , 2008, 44, 1161-1168.	2.9	45
30	Physiological and pathophysiological regulation of cytochrome P450. <i>Drug Metabolism and Disposition</i> , 1998, 26, 1232-40.	3.3	44
31	HEPATIC AND RENAL CYTOCHROME P450 GENE REGULATION DURING CITROBACTER RODENTIIUM INFECTION IN WILD-TYPE AND TOLL-LIKE RECEPTOR 4 MUTANT MICE. <i>Drug Metabolism and Disposition</i> , 2006, 34, 354-360.	3.3	43
32	TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. <i>Biochemical Pharmacology</i> , 2009, 77, 464-471.	4.4	41
33	Physiological Regulation of Drug Metabolism and Transport: Pregnancy, Microbiome, Inflammation, Infection, and Fasting. <i>Drug Metabolism and Disposition</i> , 2018, 46, 503-513.	3.3	40
34	The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice. <i>Hepatology</i> , 2015, 62, 900-914.	7.3	39
35	Suppression of P450IIC12 gene expression and elevation of actin messenger ribonucleic acid levels in the livers of female rats after injection of the interferon inducer poly rIA·poly rC. <i>Biochemical Pharmacology</i> , 1991, 42, 51-57.	4.4	36
36	Regulation of cytochrome P450 expression by sphingolipids. <i>Chemistry and Physics of Lipids</i> , 1999, 102, 131-139.	3.2	35

#	ARTICLE	IF	CITATIONS
37	Hepatic Flavin-Containing Monooxygenase Gene Regulation in Different Mouse Inflammation Models. Drug Metabolism and Disposition, 2009, 37, 462-468.	3.3	35
38	Regulation of Hepatic Cytochrome P450 Expression in Mice with Intestinal or Systemic Infections of <i>Citrobacter rodentium</i> . Drug Metabolism and Disposition, 2009, 37, 366-374.	3.3	34
39	Purification of a desmethylinipramine and debrisoquine hydroxylating cytochrome P-450 from human liver. Biochemical Pharmacology, 1986, 35, 3165-3166.	4.4	32
40	Regulation of Hepatic Cytochrome P450 2C11 by Glucocorticoids. Archives of Biochemistry and Biophysics, 1997, 345, 305-310.	3.0	32
41	Modulation of Hepatic Cytochrome P450s by <i>Citrobacter rodentium</i> Infection in Interleukin-6- and Interferon- $\gamma$ -Null Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 480-488.	2.5	29
42	Growth hormone regulates expression of rat liver cytochrome P-450 $\text{1A}_2$ at a pretranslational level. Biochemical and Biophysical Research Communications, 1987, 143, 782-788.	2.1	28
43	Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. Archives of Biochemistry and Biophysics, 2007, 461, 104-112.	3.0	27
44	Inflammatory prompts produce isoform-specific changes in the expression of leukotriene B $_4$ $\omega$ -hydroxylases in rat liver and kidney. FEBS Letters, 2003, 555, 236-242.	2.8	23
45	Nitric Oxide and Interleukin-1 $\beta$ Stimulate the Proteasome-Independent Degradation of the Retinoic Acid Hydroxylase CYP2C22 in Primary Rat Hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 141-152.	2.5	22
46	Down-regulation of phenobarbital-induced cytochrome P4502B mRNAs and proteins by endotoxin in mice: independence from nitric oxide production by inducible nitric oxide synthase. Biochemical Pharmacology, 2002, 64, 1703-1711.	4.4	21
47	Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations. Xenobiotica, 1986, 16, 391-400.	1.1	20
48	Selective role for tumor necrosis factor- $\alpha$ , but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen. Biochemical Pharmacology, 2011, 82, 312-321.	4.4	20
49	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharmaceutica Sinica B, 2017, 7, 241-248.	12.0	20
50	Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system. Free Radical Biology and Medicine, 2017, 108, 478-486.	2.9	19
51	Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease. Drug Metabolism Reviews, 2020, 52, 455-471.	3.6	19
52	Preparation and characterization of monoclonal antibodies recognizing unique epitopes on sexually differentiated rat liver cytochrome P-450 isozymes. Biochemistry, 1987, 26, 4193-4200.	2.5	18
53	Selective and Cytokine-Dependent Regulation of Hepatic Transporters and Bile Acid Homeostasis during Infectious Colitis in Mice. Drug Metabolism and Disposition, 2014, 42, 596-602.	3.3	18
54	Large scale enzyme based xenobiotic identification for exposomics. Nature Communications, 2021, 12, 5418.	12.8	18

#	ARTICLE	IF	CITATIONS
55	Alcohol oxidation by isozyme 3a of liver microsomal cytochrome P-450. <i>Pharmacology Biochemistry and Behavior</i> , 1983, 18, 177-180.	2.9	17
56	Metabolism and Action of Proteasome Inhibitors in Primary Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2010, 38, 2166-2172.	3.3	16
57	Hepatic Cytochrome P450s, Phase II Enzymes and Nuclear Receptors Are Downregulated in a Th2 Environment during <i>Schistosoma mansoni</i> Infection. <i>Drug Metabolism and Disposition</i> , 2014, 42, 134-140.	3.3	15
58	Sex-specific isozymes of P-450. <i>Steroids</i> , 1987, 49, 213-245.	1.8	12
59	Nitric oxide stimulates cellular degradation of human CYP51A1, the highly conserved lanosterol 14 $\alpha$ -demethylase. <i>Biochemical Journal</i> , 2017, 474, 3241-3252.	3.7	12
60	Selective effects of a therapeutic protein targeting tumor necrosis factor $\alpha$ on cytochrome P450 regulation during infectious colitis: implications for disease-dependent drug-drug interactions. <i>Pharmacology Research and Perspectives</i> , 2014, 2, e00027.	2.4	11
61	Altered Inflammatory Responses to <i>Citrobacter rodentium</i> Infection, but not Bacterial Lipopolysaccharide, in Mice Lacking the Cyp4a10 or Cyp4a14 Genes. <i>Inflammation</i> , 2014, 37, 893-907.	3.8	11
62	Posttranslational regulation of CYP2J2 by nitric oxide. <i>Free Radical Biology and Medicine</i> , 2018, 121, 149-156.	2.9	10
63	Nitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2. <i>Biochemical Journal</i> , 2012, 445, 377-382.	3.7	8
64	A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice. <i>Malaria Journal</i> , 2019, 18, 234.	2.3	8
65	The Dose-Response Model for Dioxin. <i>Risk Analysis</i> , 1998, 18, 1-2.	2.7	7
66	Nitric Oxide Mediated Degradation of CYP2A6 via the Ubiquitin-Proteasome Pathway in Human Hepatoma Cells. <i>Drug Metabolism and Disposition</i> , 2020, 48, 544-552.	3.3	7
67	Tyrosine nitration contributes to nitric oxide-stimulated degradation of CYP2B6. <i>Molecular Pharmacology</i> , 2020, 98, MOLPHARM-AR-2020-000020.	2.3	7
68	Tyrosine Nitration Contributes to Nitric Oxide-Stimulated Degradation of CYP2B6. <i>Molecular Pharmacology</i> , 2020, 98, 267-279.	2.3	3
69	The effect of adrenalectomy upon the absorption, distribution and metabolism of ethanol in the rat. <i>Life Sciences</i> , 1977, 21, 1033-1036.	4.3	2
70	[41] Sphingolipid-dependent signaling in regulation of cytochrome P450 expression. <i>Methods in Enzymology</i> , 1996, 272, 381-388.	1.0	2
71	Selective Modulation of Hepatic Cytochrome P450 and Flavin Monooxygenase 3 Expression during <i>Citrobacter rodentium</i> Infection in Severe Combined Immune-Deficient Mice. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1894-1899.	3.3	2
72	A Role for One or More P450 Enzymes in the Response to Sepsis. <i>Critical Care Medicine</i> , 2005, 33, 268-269.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Editorial. Drug Metabolism and Disposition, 2012, 40, 413-413.	3.3	0
74	Nitric Oxide-Dependent Proteasomal Degradation of Cytochrome P450 2B Proteins. FASEB Journal, 2006, 20, A658.	0.5	0
75	Regulation of Human Cytochrome P450 2C mRNAs by Cytokines. FASEB Journal, 2006, 20, A658.	0.5	0
76	MECHANISMS OF CYTOKINE-MEDIATED, POSTTRANSCRIPTIONAL CYP3A1 DOWN-REGULATION IN PRIMARY RAT HEPATOCYTES. FASEB Journal, 2007, 21, A195.	0.5	0
77	Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models. FASEB Journal, 2008, 22, 651-651.	0.5	0
78	Modulation of Hepatic P450, Cytokine and Acute Phase Protein mRNAs by C. rodentium Infection in Interleukin-6 and Interferon- $\gamma$ Null Mice. FASEB Journal, 2009, 23, 752.3.	0.5	0
79	Effects of T and B Cell Deficiency on Regulation of Hepatic P450 Enzymes in Mice Infected With an Intestinal Pathogen. FASEB Journal, 2012, 26, 673.12.	0.5	0
80	Evaluating Co-occurrence as a Criterion for Identification of Undocumented Xenobiotic Exposures in Human Metabolomics. FASEB Journal, 2022, 36, .	0.5	0